Takeda Pharmaceutical Co. Ltd.
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 12, 2025), Takeda Pharmaceutical Co. Ltd. reported 11 stock positions worth $26.6 million. Its top holding was Hillevax (HLVX) at 52.4% of the portfolio, followed by Ovid Therapeutics (OVID, 26.4%) and Xilio Therapeutics (XLO, 5.3%). Compared with Q3 2024, it opened 2 new positions and sold out of 1. The biggest buy was a new position in Lyell Immunopharma (LYEL) and the biggest sale an exit from Wave Life Sciences (WVE).
- Most Recent 13F
- Q3 2025
- Location
- Tokyo, M0
- CIK
- 0001395064
- Portfolio Value
- $26.6M (Q4 2024)
- SEC Filing
- 0001395064-25-000019 ↗ filed Feb 12, 2025
Holdings Value
Holdings 11 stocks · $26.6M
| HLVX Hillevax Inc. | 52.40% | 6,724,000 | $13.9M | No change |
| OVID Ovid Therapeutics Inc. | 26.40% | 7,531,996 | $7.0M | No change |
| XLO Xilio Therapeutics Inc. | 5.33% | 1,475,121 | $1.4M | No change |
| EQ Equillium Inc. | 5.15% | 1,824,977 | $1.4M | No change |
| STTK Shattuck Labs Inc. | 2.35% | 515,619 | $624K | No change |
| AMWL American Well Corp. Class A | 2.12% | 77,733 | $564K | No change |
| LYEL Lyell Immunopharma Inc. | 1.98% | 823,317 | $527K | New |
| TSBX Turnstone Biologics Corp. | 1.69% | 895,824 | $448K | No change |
| THRD Third Harmonic Bio Inc. | 1.43% | 36,835 | $379K | New |
| RANI Rani Therapeutics Holdings Class A | 1.05% | 203,190 | $278K | No change |
| LAB Standard Biotools Inc. | 0.11% | 16,515 | $29K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| WVE Wave Life Sciences Ltd. | Sold out | 0.00% | −29.10 |
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q3 2025 | 8 | $16.4M | OVID, EQ, XLO, STTK, LYEL |
| Q2 2025 | 11 | $19.6M | HLVX, OVID, XLO, AMWL, EQ |
| Q1 2025 | 11 | $16.2M | HLVX, OVID, XLO, EQ, AMWL |
| Q4 2024 | 11 | $26.6M | HLVX, OVID, XLO, EQ, STTK |
| Q3 2024 | 10 | $38.0M | HLVX, WVE, OVID, STTK, EQ |
| Q2 2024 | 13 | $232.3M | DNLI, HLVX, PHAT, WVE, OVID |
| Q1 2024 | 15 | $289.0M | HLVX, DNLI, PHAT, OVID, STTK |